David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical ...

Cladribine (Mavenclad, Merck Serono) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features'.

Annalisa Jenkins, the former head of R&D at Merck Serono, is one of the people behind the investment fund.

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer The following represents disclosure information provided ...

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

Goldman Sachs analyst Asad Haider assumed coverage of Merck (MRK) with a Buy rating and price target of $103, down from $129. Following the recent selloff, the shares are now trading at levels ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).

with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...

Thanks to David Krumholtz of "The Santa Clause" fame, we've gotten our very first glimpse at the official logo for next year's "Supergirl: Woman of Tomorrow"... or perhaps just "Supergirl"?